203 related articles for article (PubMed ID: 35703080)
21. The role of anthranilic acid in the increase of depressive symptoms and major depressive disorder during treatment for hepatitis C with pegylated interferon-α2a and oral ribavirin.
Pawlowski T; Pawlak D; Inglot M; Zalewska M; Marciniak D; Bugajska J; Janocha-Litwin J; Malyszczak K
J Psychiatry Neurosci; 2021 Jan; 46(1):E166-E175. PubMed ID: 33464780
[TBL] [Abstract][Full Text] [Related]
22. Neuroimaging-aided differential diagnosis of the depressive state.
Takizawa R; Fukuda M; Kawasaki S; Kasai K; Mimura M; Pu S; Noda T; Niwa S; Okazaki Y;
Neuroimage; 2014 Jan; 85 Pt 1():498-507. PubMed ID: 23764293
[TBL] [Abstract][Full Text] [Related]
23. Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study.
Li CT; Bai YM; Huang YL; Chen YS; Chen TJ; Cheng JY; Su TP
Br J Psychiatry; 2012 Jan; 200(1):45-51. PubMed ID: 22016435
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of major depressive disorder in the general population of Iran: A systematic review and meta-analysis.
Gharraee B; Zahedi Tajrishi K; Sheybani F; Tahmasbi N; Mirzaei M; Farahani H; Naserbakht M
Med J Islam Repub Iran; 2019; 33():151. PubMed ID: 32280657
[No Abstract] [Full Text] [Related]
25. Associations between age and the course of major depressive disorder: a 2-year longitudinal cohort study.
Schaakxs R; Comijs HC; Lamers F; Kok RM; Beekman ATF; Penninx BWJH
Lancet Psychiatry; 2018 Jul; 5(7):581-590. PubMed ID: 29887519
[TBL] [Abstract][Full Text] [Related]
26. [Use of health services and treatments for major depressive episode in France].
Lamboy B; Léon C
Encephale; 2006 Oct; 32(5 Pt 1):705-12. PubMed ID: 17099594
[TBL] [Abstract][Full Text] [Related]
27. An Analysis of Two Genome-wide Association Meta-analyses Identifies a New Locus for Broad Depression Phenotype.
Direk N; Williams S; Smith JA; Ripke S; Air T; Amare AT; Amin N; Baune BT; Bennett DA; Blackwood DHR; Boomsma D; Breen G; Buttenschøn HN; Byrne EM; Børglum AD; Castelao E; Cichon S; Clarke TK; Cornelis MC; Dannlowski U; De Jager PL; Demirkan A; Domenici E; van Duijn CM; Dunn EC; Eriksson JG; Esko T; Faul JD; Ferrucci L; Fornage M; de Geus E; Gill M; Gordon SD; Grabe HJ; van Grootheest G; Hamilton SP; Hartman CA; Heath AC; Hek K; Hofman A; Homuth G; Horn C; Jan Hottenga J; Kardia SLR; Kloiber S; Koenen K; Kutalik Z; Ladwig KH; Lahti J; Levinson DF; Lewis CM; Lewis G; Li QS; Llewellyn DJ; Lucae S; Lunetta KL; MacIntyre DJ; Madden P; Martin NG; McIntosh AM; Metspalu A; Milaneschi Y; Montgomery GW; Mors O; Mosley TH; Murabito JM; Müller-Myhsok B; Nöthen MM; Nyholt DR; O'Donovan MC; Penninx BW; Pergadia ML; Perlis R; Potash JB; Preisig M; Purcell SM; Quiroz JA; Räikkönen K; Rice JP; Rietschel M; Rivera M; Schulze TG; Shi J; Shyn S; Sinnamon GC; Smit JH; Smoller JW; Snieder H; Tanaka T; Tansey KE; Teumer A; Uher R; Umbricht D; Van der Auwera S; Ware EB; Weir DR; Weissman MM; Willemsen G; Yang J; Zhao W; Tiemeier H; Sullivan PF
Biol Psychiatry; 2017 Sep; 82(5):322-329. PubMed ID: 28049566
[TBL] [Abstract][Full Text] [Related]
28. A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients.
Li G; Zhang L; DiBernardo A; Wang G; Sheehan JJ; Lee K; Reutfors J; Zhang Q
PLoS One; 2020; 15(9):e0238843. PubMed ID: 32915863
[TBL] [Abstract][Full Text] [Related]
29. Body mass index and childhood symptoms of depression, anxiety, and attention-deficit hyperactivity disorder: A within-family Mendelian randomization study.
Hughes AM; Sanderson E; Morris T; Ayorech Z; Tesli M; Ask H; Reichborn-Kjennerud T; Andreassen OA; Magnus P; Helgeland Ø; Johansson S; Njølstad P; Davey Smith G; Havdahl A; Howe LD; Davies NM
Elife; 2022 Dec; 11():. PubMed ID: 36537070
[TBL] [Abstract][Full Text] [Related]
30. Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial.
Dean OM; Kanchanatawan B; Ashton M; Mohebbi M; Ng CH; Maes M; Berk L; Sughondhabirom A; Tangwongchai S; Singh AB; McKenzie H; Smith DJ; Malhi GS; Dowling N; Berk M
Aust N Z J Psychiatry; 2017 Aug; 51(8):829-840. PubMed ID: 28578592
[TBL] [Abstract][Full Text] [Related]
31. Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD).
Dold M; Bartova L; Fugger G; Kautzky A; Souery D; Mendlewicz J; Papadimitriou GN; Dikeos D; Ferentinos P; Porcelli S; Serretti A; Zohar J; Montgomery S; Kasper S
Int J Neuropsychopharmacol; 2018 Jun; 21(6):539-549. PubMed ID: 29860382
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of comorbid major depressive disorder in Type 2 diabetes: a meta-analysis of comparative and epidemiological studies.
Wang F; Wang S; Zong QQ; Zhang Q; Ng CH; Ungvari GS; Xiang YT
Diabet Med; 2019 Aug; 36(8):961-969. PubMed ID: 31127631
[TBL] [Abstract][Full Text] [Related]
33. Designing poly(gamma-aminobutyric acid)-based nanoparticles for the treatment of major depressive disorders.
Tri BD; Shashni B; Matsui H; Nagasaki Y
J Control Release; 2023 Aug; 360():110-121. PubMed ID: 37336293
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine.
Serrano-Blanco A; Gabarron E; Garcia-Bayo I; Soler-Vila M; Caramés E; Peñarrubia-Maria MT; Pinto-Meza A; Haro JM;
J Affect Disord; 2006 Apr; 91(2-3):153-63. PubMed ID: 16458976
[TBL] [Abstract][Full Text] [Related]
35. Add-on benzodiazepine treatment in patients with major depressive disorder - results from a European cross-sectional multicenter study.
Dold M; Bartova L; Fugger G; Mitschek MMM; Kautzky A; Frey R; Montgomery S; Zohar J; Mendlewicz J; Souery D; Fabbri C; Serretti A; Kasper S
Eur Neuropsychopharmacol; 2020 Dec; 41():70-80. PubMed ID: 33046351
[TBL] [Abstract][Full Text] [Related]
36. Abnormal functional connectivity strength in first-episode, drug-naïve adult patients with major depressive disorder.
Shi Y; Li J; Feng Z; Xie H; Duan J; Chen F; Yang H
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Mar; 97():109759. PubMed ID: 31499128
[TBL] [Abstract][Full Text] [Related]
37. Global pattern of experienced and anticipated discrimination reported by people with major depressive disorder: a cross-sectional survey.
Lasalvia A; Zoppei S; Van Bortel T; Bonetto C; Cristofalo D; Wahlbeck K; Bacle SV; Van Audenhove C; van Weeghel J; Reneses B; Germanavicius A; Economou M; Lanfredi M; Ando S; Sartorius N; Lopez-Ibor JJ; Thornicroft G;
Lancet; 2013 Jan; 381(9860):55-62. PubMed ID: 23083627
[TBL] [Abstract][Full Text] [Related]
38. A model of the economic impact of a bipolar disorder screening program in primary care.
Menzin J; Sussman M; Tafesse E; Duczakowski C; Neumann P; Friedman M
J Clin Psychiatry; 2009 Sep; 70(9):1230-6. PubMed ID: 19689919
[TBL] [Abstract][Full Text] [Related]
39. Glial mechanisms underlying major depressive disorder: Potential therapeutic opportunities.
Rahman S; Alzarea S
Prog Mol Biol Transl Sci; 2019; 167():159-178. PubMed ID: 31601403
[TBL] [Abstract][Full Text] [Related]
40. Brain white-matter hyperintensities and treatment outcome in major depressive disorder.
Iosifescu DV; Renshaw PF; Lyoo IK; Lee HK; Perlis RH; Papakostas GI; Nierenberg AA; Fava M
Br J Psychiatry; 2006 Feb; 188():180-5. PubMed ID: 16449707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
